Radiolabelled FGF-2 for Imaging Activated Fibroblasts in the Tumor Micro-Environment DOI Creative Commons
Valeria Bentivoglio, Filippo Galli, Michela Varani

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(4), P. 491 - 491

Published: April 18, 2024

Tumor associated fibroblasts (TAFs) play a key role in tumor growth and metastatization. TAFs overexpress different biomarkers that are usually expressed at low levels physiological conditions. Among them the fibroblast factor receptors (FGFRs) bind factors (FGFs). In particular, overexpression of FGFR-2c tumors has been with advanced clinical stages increased Here, we developed non-invasive tool to evaluate, vivo, expression metastatic cancer. This is based on

Language: Английский

FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer? DOI Creative Commons
Irene García Megías, Ludmila Santiago Almeida, Adriana K. Calapaquí Terán

et al.

Annals of Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Abstract [ 18 F]FDG PET/CT is the most widely used PET radiopharmaceutical in oncology, but it not exempt of diagnostic limitations. FAPI have emerged as a great tool management several different solid tumours which able to provide enough information. The aim this work was evaluate available evidence on and therapeutic applications with radiopharmaceuticals. We underwent non-systematic review focusing utility radiopharmaceuticals diagnosis treatment malignancies. present characteristics that can potentially overcome some known limitations F]FDG. high target-to-background ratio (TBR) many such oesophageal cancer, gastric pancreatic hepatic colorectal breast ovarian, cervical head neck cancer. Available suggests TBR improves sensitivity specificity compared F]FDG, especially for detection lymphadenopathies peritoneal metastases, may improve patient radiation planning. Moreover, important underline potential theranostic application

Language: Английский

Citations

2
FAPI-PET/CT guided radiotherapy for patients with esophageal cancer DOI Creative Commons

Kai Kröger,

Niklas Benedikt Pepper, David Ventura

et al.

Radiation Oncology, Journal Year: 2025, Volume and Issue: 20(1)

Published: Feb. 28, 2025

Language: Английский

Citations

0
Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics DOI Creative Commons
William Serumula,

Venesen Pillay,

Bawinile Hadebe

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 522 - 522

Published: April 3, 2025

Fibroblast activation protein (FAP) is a serine protease selectively expressed in cancer-associated fibroblasts (CAFs), fibrotic tissues, and areas of active tissue remodeling, making it an attractive target for diagnostic imaging across spectrum disease. FAP inhibitors (FAPIs) labeled with PET tracers have rapidly advanced as novel modality broad clinical applications that offers several advantages, including rapid tumor accumulation, low background uptake, high tumor-to-background ratios. In oncology, FAPI has demonstrated excellent performance visualizing wide range malignancies, those glycolytic activity, such pancreatic cancer, cholangiocarcinoma, certain sarcomas. Its sensitivity specificity the stromal component enables improved delineation, staging, response assessment. Additionally, potential to guide theranostic approaches, where same tracer can be therapeutic radionuclides, positions key player precision oncology. Beyond shown promise conditions characterized by inflammatory processes. cardiovascular field, being investigated its ability detect myocardial fibrosis cardiac crucial like heart failure, post-myocardial infarction hypertrophic cardiomyopathy. This review highlights expanding FAPI-based inflammation, While current data are promising, further large-scale studies multicenter trials essential validate these findings establish standardized protocols. The versatility applicability underscore transformative tool medicine.

Language: Английский

Citations

0
FAPI PET Versus FDG PET/CT in Gastrointestinal Cancers: An Overview DOI Creative Commons

Zhaoguo Lin,

Pawel Rasinski, Ted Nilsson

et al.

Seminars in Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Fibroblast activation protein (FAP) is a type II transmembrane serine protease that highly expressed in cancer-associated fibroblasts (CAFs) but absent quiescent fibroblasts. Its overexpression associated with poor prognosis various cancers and contributes to treatment resistance. In recent years, radiolabeled FAP inhibitors (FAPI) for PET imaging have shown promising clinical value across range of cancers. Gastrointestinal (GI) malignancies, which often exhibit desmoplastic reaction high density FAP-expressing CAFs, are particularly well-suited FAPI PET. Given the limitations [18F]FDG GI cancers, such as low sensitivity certain histological subtypes physiological background uptake, expected serve complementary method, potentially enhancing both diagnostic accuracy guidance. This review provides comprehensive comparison applications including their diagnosis, staging, Additionally, this summarizes studies on expanding role PET, its use assessing response predicting prognosis, aiming provide insights into potential contribution improved management malignancies.

Language: Английский

Citations

0
One-Stop 68Ga-FAPI/18F-FDG Total-Body PET/CT Scan DOI

Huaping Gao,

Han Tang,

Zhe Zheng

et al.

Clinical Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 24, 2025

Purpose: This prospective study aims to assess the feasibility of a one-stop imaging protocol using 68 Ga-FAPI-04/ 18 F-FDG dual-radiotracer with dual-low-activity for tumor imaging. Patients and Methods: Forty patients underwent Ga-FAPI-04 PET (PET FAPI ) DUAL total-body PET/CT scanner 194-cm axial field view. After half-dose (0.925 MBq/kg) PET/CT, an additional (1.85 was administered 60-minute dynamic acquisition. reconstructed at 10-minute intervals D0–10 , D10–20 D20–30 D30–40 D40–50 D50–60 ). Data lesion detectability, target-to-background ratios, staging, total radiation dose were analyzed. A target-to-liver ratio (TLR) ≥ 3 on considered indicative sufficient fibroblast activation protein expression. Results: showed similar performance in detecting primary tumors (42 vs 41, P > 0.999). However, significantly more metastatic lesions identified compared (102 60, < 0.001). demonstrated higher TLR, target-to-blood-pool ratio, target-to-normal-tissue than ( 0.05). Lesion detectability across (all ’s Notably, detected all by . no significant differences Up 94.9% malignant exhibited TLR The average effective 9.85 ± 2.19 mSv, that whole-body PET/CT. Conclusions: one-stop, dual-radiotracer, combines strengths F-FDG, offering shorter duration reduced exposure.

Language: Английский

Citations

0
Radiolabelled FGF-2 for Imaging Activated Fibroblasts in the Tumor Micro-Environment DOI Creative Commons
Valeria Bentivoglio, Filippo Galli, Michela Varani

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(4), P. 491 - 491

Published: April 18, 2024

Tumor associated fibroblasts (TAFs) play a key role in tumor growth and metastatization. TAFs overexpress different biomarkers that are usually expressed at low levels physiological conditions. Among them the fibroblast factor receptors (FGFRs) bind factors (FGFs). In particular, overexpression of FGFR-2c tumors has been with advanced clinical stages increased Here, we developed non-invasive tool to evaluate, vivo, expression metastatic cancer. This is based on

Language: Английский

Citations

1